

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Smell and taste dysfunction in COVID-19 patients, nasal vaccines, preventive medication for COVID-19 infection

#### Peer reviewed journals featured:

- A systematic review on the prognosis and persistence of smell and taste dysfunction in COVID-19 patients [here](#), associated editorial [here](#) and commentary [here](#)
- A randomised trial of text message reminders and vaccine reservations to support uptake [here](#)
- A narrative review on isolation facilities for COVID-19 [here](#)
- Observational studies on:
  - Immune response to Comirnaty (Pfizer) vaccine in patients with autoimmune inflammatory rheumatic diseases [here](#)
  - Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease [here](#)
  - mRNA vaccine booster protection against Omicron in patients with autoimmune rheumatic diseases [here](#)
  - Reversals of COVID-19 vaccination hesitancy among Japanese people [here](#) and [here](#)
  - Tracking the pandemic using wastewater monitoring [here](#) and [here](#)
  - Symptoms and risk factors for long COVID in non-hospitalised adults [here](#)
  - In vitro activity of therapeutic antibodies against Omicron BA.1, BA.2 and BA.5 [here](#)
  - Post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark [here](#)
  - Risk of severe COVID-19 infection among adults with prior exposure to children [here](#)
  - Vaccination effectiveness after COVID-19 recovery in preventing reinfection [here](#)
  - Mapping the Huanan market in Wuhan as the early epicentre of the pandemic [here](#)
  - Antibody responses in children following mRNA COVID-19 vaccination [here](#)
  - Post-COVID-19 conditions among children 90 days after SARS-CoV-2 infection [here](#)
- An editorial on nasal vaccines for COVID-19 [here](#)
- Commentary on an effective international pandemic treaty and accountability [here](#)
- A JAMA patient guide to preventive medication for COVID-19 infection [here](#)

#### Letters and correspondence discussed:

- Trends in diabetes incidence among children during COVID-19 in Ontario [here](#)
- Vaccination and acute myocardial infarction and ischaemic stroke after COVID-19 infection [here](#)
- Safety and adverse events in long-term care residents receiving a third mRNA booster dose [here](#)

- Antibody titres after third and fourth Comirnaty (Pfizer) doses in older adults [here](#) and [here](#)
- Masks for preventing respiratory virus infections including SARS-CoV-2 [here](#)
- Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine [here](#)

### Pre-peer review articles featured:

- Durability of the neutralising antibody response to mRNA booster against Omicron BA.2.12.1 and BA.4/5 variants [here](#)
- Duration of Omicron BA.5 neutralisation in sera and nasal swabs from vaccinated individuals [here](#)
- Lowered quality of life in long COVID associated with inflammatory processes [here](#)
- Omicron BA.5 vaccine breakthrough risk and severity compared with BA.2 [here](#)
- Primary Omicron infection, antibody responses and cellular immunity in children [here](#)
- Evasion of neutralising antibodies by Omicron sublineage BA.2.75 [here](#)
- COVID-19 and long term peripheral nerve demyelination and axonal loss [here](#)

### Guidance and reports

- The World Health Organisation published:
  - Its weekly epidemiological report on COVID-19 [here](#)
  - Guidance on public health surveillance for COVID-19 [here](#) and case definition [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)
- The UNSW Kirby Institute released an updated report on seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors [here](#)

### News and blogs

- Prior Omicron infection protects against BA.4 and BA.5 variants [here](#)
- Hair loss and sexual dysfunction are among wider symptoms of long COVID [here](#)
- COVID-19 infection raises risk of diabetes and heart disease diagnoses in following weeks [here](#)
- China approves first homegrown COVID-19 antiviral [here](#)
- How long is COVID-19 infectious? [here](#)
- Pandemic drives largest drop in international childhood vaccinations in 30 years [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).



Health

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.